thalidomide has been researched along with Malignant Melanoma in 42 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase 1 study evaluated the safety and tolerability of adjuvant treatment with subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF) administered in combination with escalating doses of thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high risk for recurrence." | 9.14 | A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. ( Gillett, M; Lutzky, J; Nunez, Y; Spitler, L; Weber, R, 2009) |
| "The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to proceed with additional trials of this combination." | 9.14 | Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009) |
| " The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma." | 9.14 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 9.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 9.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "This phase I trial assessed the maximal tolerated dose (MTD) of dacarbazine in combination with lenalidomide in metastatic melanoma." | 9.14 | Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. ( Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010) |
| "There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases." | 9.13 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008) |
| "Patients with melanoma, CNS metastases documented by magnetic resonance imaging, and no prior systemic chemotherapy received WBRT, 30 Gray in 10 fractions, Days 1 to 5 and 8 to 12; TMZ, 75 mg/m(2)/day, Weeks 1 to 6; and thalidomide, 100 mg/day, Weeks 1 to 4, then escalated by 100 mg/day at Weeks 5, 7, and 9 as tolerated to a maximum of 400 mg/day." | 9.13 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "The combination of temozolomide and thalidomide is well tolerated in patients with very advanced heavily pretreated metastatic melanoma." | 9.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 9.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma." | 9.12 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007) |
| "Pegylated interferon and thalidomide demonstrate immunomodulatory and antiangiogenic activity, and efficacy in melanoma." | 9.12 | Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. ( Flaherty, LE; Heilbrun, LK; Marsack, C; Smith, DW; Vaishampayan, UN, 2007) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 9.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years)." | 9.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The combination of temozolomide and thalidomide was well tolerated and had antitumor activity in patients with advanced melanoma, including elderly patients over 70 years old." | 9.10 | Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ, 2002) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases." | 9.10 | Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003) |
| "To observe the effects of thalidomide on melanoma tumor growth and blood supply patterns in C57 mice." | 7.74 | Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. ( Cui, Y; Gu, Y; Li, M; Liu, Z; Sun, B; Xu, S; Zhang, S, 2008) |
| "Melanoma is a hypervascular tumor and angiogenesis plays a critical role in the development/progression of metastases." | 6.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Thalidomide was given orally at a daily dose of 200 mg/day, which was then escalated every 2 weeks by 200 mg/day as tolerated to a maximum of 800 mg/day." | 6.71 | Phase II study of thalidomide in patients with metastatic malignant melanoma. ( Cancela, AI; Costa, TD; Di Leone, LP; Fernandes, S; Reiriz, AB; Richter, MF; Schwartsmann, G, 2004) |
| " In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment." | 6.71 | Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. ( Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J, 2004) |
| "Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy." | 6.69 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. ( Ahern, R; Boshoff, C; Eisen, T; Gore, ME; Johnston, SR; Mak, I; Pyle, L; Sapunar, F; Smith, IE; Vaughan, MM, 2000) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 6.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "This phase 1 study evaluated the safety and tolerability of adjuvant treatment with subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF) administered in combination with escalating doses of thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high risk for recurrence." | 5.14 | A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. ( Gillett, M; Lutzky, J; Nunez, Y; Spitler, L; Weber, R, 2009) |
| "The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to proceed with additional trials of this combination." | 5.14 | Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009) |
| " The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma." | 5.14 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 5.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "This phase I trial assessed the maximal tolerated dose (MTD) of dacarbazine in combination with lenalidomide in metastatic melanoma." | 5.14 | Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. ( Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 5.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "Patients with melanoma, CNS metastases documented by magnetic resonance imaging, and no prior systemic chemotherapy received WBRT, 30 Gray in 10 fractions, Days 1 to 5 and 8 to 12; TMZ, 75 mg/m(2)/day, Weeks 1 to 6; and thalidomide, 100 mg/day, Weeks 1 to 4, then escalated by 100 mg/day at Weeks 5, 7, and 9 as tolerated to a maximum of 400 mg/day." | 5.13 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008) |
| "There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases." | 5.13 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008) |
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 5.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "The combination of temozolomide and thalidomide is well tolerated in patients with very advanced heavily pretreated metastatic melanoma." | 5.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Pegylated interferon and thalidomide demonstrate immunomodulatory and antiangiogenic activity, and efficacy in melanoma." | 5.12 | Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. ( Flaherty, LE; Heilbrun, LK; Marsack, C; Smith, DW; Vaishampayan, UN, 2007) |
| "Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma." | 5.12 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007) |
| "Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years)." | 5.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 5.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases." | 5.10 | Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "The combination of temozolomide and thalidomide was well tolerated and had antitumor activity in patients with advanced melanoma, including elderly patients over 70 years old." | 5.10 | Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ, 2002) |
| "To observe the effects of thalidomide on melanoma tumor growth and blood supply patterns in C57 mice." | 3.74 | Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. ( Cui, Y; Gu, Y; Li, M; Liu, Z; Sun, B; Xu, S; Zhang, S, 2008) |
| "Migration of HUVEC cells, the ability of HUVEC cells to form tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination." | 3.74 | Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. ( Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI, 2007) |
| "In this report, we describe two new venous thrombosis cases occurring during a treatment with thalidomide." | 3.71 | [Thrombotic accidents induced by thalidomide: two cases]. ( Gachon, J; Grob, JJ; Richard, MA, 2002) |
| ", 1991), we found that pentoxifylline and thalidomide potentiate each others antiangiogenic effect induced by human malignant melanoma cells in the cornea of Macaca arctoides monkeys." | 3.70 | Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration. ( Akhter, S; Ambrus, JL; Karakousis, CP; Kulaylat, M; Plavsic, L; Toumbis, CA, 2000) |
| "Melanoma is a hypervascular tumor and angiogenesis plays a critical role in the development/progression of metastases." | 2.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Thalidomide was given orally at a daily dose of 200 mg/day, which was then escalated every 2 weeks by 200 mg/day as tolerated to a maximum of 800 mg/day." | 2.71 | Phase II study of thalidomide in patients with metastatic malignant melanoma. ( Cancela, AI; Costa, TD; Di Leone, LP; Fernandes, S; Reiriz, AB; Richter, MF; Schwartsmann, G, 2004) |
| " In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment." | 2.71 | Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. ( Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J, 2004) |
| "Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy." | 2.69 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. ( Ahern, R; Boshoff, C; Eisen, T; Gore, ME; Johnston, SR; Mak, I; Pyle, L; Sapunar, F; Smith, IE; Vaughan, MM, 2000) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 2.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (85.71) | 29.6817 |
| 2010's | 5 (11.90) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Rathod, D | 1 |
| Fu, Y | 1 |
| Patel, K | 1 |
| Foti, C | 1 |
| Tucci, M | 1 |
| Stingeni, L | 1 |
| Hansel, K | 1 |
| Lospalluti, L | 1 |
| Frisario, R | 1 |
| Giuffrida, R | 1 |
| Romita, P | 1 |
| Said, R | 1 |
| Kakadiaris, E | 1 |
| Piha-Paul, S | 1 |
| Fu, S | 1 |
| Falchook, G | 1 |
| Janku, F | 1 |
| Wheler, JJ | 1 |
| Zinner, R | 1 |
| Hong, DS | 1 |
| Kurzrock, R | 1 |
| Tsimberidou, AM | 1 |
| Vestermark, LW | 1 |
| Larsen, S | 1 |
| Lindeløv, B | 1 |
| Bastholt, L | 1 |
| Atkins, MB | 2 |
| Sosman, JA | 2 |
| Agarwala, S | 1 |
| Logan, T | 1 |
| Clark, JI | 3 |
| Ernstoff, MS | 1 |
| Lawson, D | 1 |
| Dutcher, JP | 1 |
| Weiss, G | 1 |
| Curti, B | 1 |
| Margolin, KA | 1 |
| Zhang, S | 1 |
| Li, M | 1 |
| Gu, Y | 1 |
| Liu, Z | 1 |
| Xu, S | 1 |
| Cui, Y | 1 |
| Sun, B | 1 |
| Lutzky, J | 1 |
| Weber, R | 1 |
| Nunez, Y | 1 |
| Gillett, M | 1 |
| Spitler, L | 1 |
| Ott, PA | 1 |
| Chang, JL | 1 |
| Oratz, R | 1 |
| Jones, A | 1 |
| Farrell, K | 1 |
| Muggia, F | 1 |
| Pavlick, AC | 1 |
| Glaspy, J | 2 |
| Richards, JM | 1 |
| Agarwala, SS | 1 |
| O'Day, S | 1 |
| Knight, RD | 3 |
| Jungnelius, JU | 2 |
| Bedikian, AY | 1 |
| Eisen, T | 2 |
| Trefzer, U | 1 |
| Hamilton, A | 1 |
| Hersey, P | 1 |
| Millward, M | 1 |
| Moon, J | 2 |
| Hutchins, LF | 2 |
| Kast, WM | 1 |
| Da Silva, DM | 1 |
| Liu, PY | 1 |
| Thompson, JA | 2 |
| Flaherty, LE | 3 |
| Sondak, VK | 3 |
| Hwu, WJ | 7 |
| Patnana, M | 1 |
| Bassett, R | 1 |
| Papadopoulos, NE | 1 |
| Kim, KB | 1 |
| Hwu, P | 1 |
| Bedikian, A | 1 |
| Gachon, J | 1 |
| Grob, JJ | 1 |
| Richard, MA | 1 |
| Bajetta, E | 1 |
| Del Vecchio, M | 1 |
| Bernard-Marty, C | 1 |
| Vitali, M | 1 |
| Buzzoni, R | 1 |
| Rixe, O | 1 |
| Nova, P | 1 |
| Aglione, S | 1 |
| Taillibert, S | 1 |
| Khayat, D | 1 |
| Marriott, JB | 1 |
| Clarke, IA | 2 |
| Czajka, A | 1 |
| Dredge, K | 2 |
| Childs, K | 1 |
| Man, HW | 1 |
| Schafer, P | 1 |
| Govinda, S | 1 |
| Muller, GW | 3 |
| Stirling, DI | 3 |
| Dalgleish, AG | 2 |
| Danson, S | 1 |
| Lorigan, P | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Ranson, M | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 1 |
| Middleton, MR | 1 |
| Krown, SE | 4 |
| Menell, JH | 3 |
| Panageas, KS | 4 |
| Merrell, J | 2 |
| Lamb, LA | 2 |
| Williams, LJ | 3 |
| Quinn, CJ | 2 |
| Foster, T | 1 |
| Chapman, PB | 3 |
| Livingston, PO | 3 |
| Wolchok, JD | 2 |
| Houghton, AN | 4 |
| Lang, NP | 1 |
| Bartlett, JB | 1 |
| Michael, A | 1 |
| Nicholson, S | 1 |
| Kristeleit, H | 1 |
| Polychronis, A | 1 |
| Pandha, H | 1 |
| Zeldis, J | 1 |
| Pawlak, WZ | 1 |
| Legha, SS | 1 |
| Sengupta, S | 1 |
| Kiziltepe, T | 1 |
| Sasisekharan, R | 1 |
| Reiriz, AB | 1 |
| Richter, MF | 1 |
| Fernandes, S | 1 |
| Cancela, AI | 1 |
| Costa, TD | 1 |
| Di Leone, LP | 1 |
| Schwartsmann, G | 1 |
| Lis, E | 2 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Heere-Ress, E | 1 |
| Boehm, J | 1 |
| Thallinger, C | 1 |
| Hoeller, C | 1 |
| Wacheck, V | 1 |
| Birner, P | 1 |
| Wolff, K | 1 |
| Pehamberger, H | 1 |
| Jansen, B | 1 |
| Mita, MM | 1 |
| Rowinsky, EK | 1 |
| Forero, L | 1 |
| Eckhart, SG | 1 |
| Izbicka, E | 1 |
| Weiss, GR | 1 |
| Beeram, M | 1 |
| Mita, AC | 1 |
| de Bono, JS | 1 |
| Tolcher, AW | 1 |
| Hammond, LA | 1 |
| Simmons, P | 1 |
| Berg, K | 1 |
| Takimoto, C | 1 |
| Patnaik, A | 1 |
| Laber, DA | 1 |
| Okeke, RI | 1 |
| Arce-Lara, C | 1 |
| Taft, BS | 1 |
| Schonard, CL | 1 |
| McMasters, KM | 1 |
| Kloecker, GH | 1 |
| Miller, DM | 1 |
| Niedzwiecki, D | 1 |
| Hodgson, L | 1 |
| Haluska, FG | 1 |
| Kawamata, A | 1 |
| Ito, D | 1 |
| Odani, T | 1 |
| Isobe, T | 1 |
| Iwase, M | 1 |
| Hatori, M | 1 |
| Nagumo, M | 1 |
| Solti, M | 1 |
| Berd, D | 1 |
| Mastrangelo, MJ | 1 |
| Sato, T | 1 |
| Mangiameli, DP | 1 |
| Blansfield, JA | 1 |
| Kachala, S | 1 |
| Lorang, D | 1 |
| Schafer, PH | 1 |
| Libutti, SK | 1 |
| Vaishampayan, UN | 1 |
| Heilbrun, LK | 1 |
| Marsack, C | 1 |
| Smith, DW | 1 |
| Lange, MK | 1 |
| Boshoff, C | 1 |
| Mak, I | 1 |
| Sapunar, F | 1 |
| Vaughan, MM | 1 |
| Pyle, L | 1 |
| Johnston, SR | 1 |
| Ahern, R | 1 |
| Smith, IE | 1 |
| Gore, ME | 1 |
| Eisen, TG | 2 |
| Ambrus, JL | 1 |
| Toumbis, CA | 1 |
| Karakousis, CP | 1 |
| Kulaylat, M | 1 |
| Akhter, S | 1 |
| Plavsic, L | 1 |
| Kudva, GC | 1 |
| Collins, BT | 1 |
| Dunphy, FR | 1 |
| Nathan, PD | 1 |
| Raizer, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy[NCT00057616] | Phase 3 | 274 participants | Interventional | 2002-10-01 | Completed | ||
| A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988] | Phase 2 | 64 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy[NCT00179608] | Phase 1 | 28 participants | Interventional | 2005-09-01 | Completed | ||
| Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer[NCT06017284] | Phase 3 | 100 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma[NCT00005815] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-12-31 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II[NCT00026520] | Phase 2 | 0 participants | Interventional | 2001-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
5 reviews available for thalidomide and Malignant Melanoma
| Article | Year |
|---|---|
Metastatic melanoma: chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carbo | 2002 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Thalidomide in solid tumors: the London experience.
Topics: Adult; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II a | 2000 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
The biological treatment of renal-cell carcinoma and melanoma.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Hematopoietic Stem Cell Transplantation; Hu | 2002 |
23 trials available for thalidomide and Malignant Melanoma
| Article | Year |
|---|---|
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2016 |
A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; F | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Human | 2009 |
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lenalidomi | 2009 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Respo | 2010 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytokines; Female; Fibroblast G | 2004 |
Phase II study of thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Humans; Lung Neoplasms; Male; Max | 2004 |
Phase II study of thalidomide in patients with metastatic malignant melanoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Fi | 2004 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug; | 2007 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2007 |
Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma | 2007 |
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Topics: Adult; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Lymphokines; Male; Me | 2000 |
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; | 2002 |
14 other studies available for thalidomide and Malignant Melanoma
| Article | Year |
|---|---|
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Caco-2 Cells; Cell Cycle Proteins; Cell Line, Tumor; Dru | 2019 |
Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Melanoma; Nivolumab; Psoriasis; Severity of Illness | 2021 |
Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma.
Topics: Angiogenesis Inhibitors; Animals; Immunohistochemistry; Matrix Metalloproteinase 2; Matrix Metallopr | 2008 |
[Thrombotic accidents induced by thalidomide: two cases].
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Vulgaris; Male; Melanoma; Multiple Myel | 2002 |
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associa | 2003 |
Molecular epidemiology: new insights into diagnosis and prognosis.
Topics: Alleles; Angiogenesis Inhibitors; Breast Neoplasms; Colonic Neoplasms; Female; Gene Expression; Glut | 2004 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; D | 2004 |
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Comb | 2005 |
Advances in the understanding and treatment of melanoma -- Keystone Symposium.
Topics: Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Humans; Imiquimo | 2006 |
Thalidomide suppresses melanoma growth by activating natural killer cells in mice.
Topics: Actins; Animals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Chemokine CXCL10; Chemokines, CXC; | 2006 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Prol | 2007 |
Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Cornea; Corneal Neovascularization; Drug Combinat | 2000 |
Thalidomide for malignant melanoma.
Topics: Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Thalidomide | 2001 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |